Neurodegenerative disorders associated with anti-IgLON5 antibodies are frequently characterized by sleep behavior disorder and bulbar symptoms (39, 58), but anti-igLON5 disease symptoms has a wider range expressing a clinical picture overlapping with disorders such as Alzheimer’s disease (AD) (59, 60), corticobasal degeneration (CBD) (61) progressive supranuclear palsy (PSP) (62, 63). The gene discussed is IGLON5; the disease is early-onset autosomal dominant Alzheimer disease.